This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2020 Jul 23;383(4):389-390.

doi: 10.1056/NEJMe2022702. Epub 2020 Jul 8.

Baloxavir for Postexposure Prophylaxis against Influenza in Households

Timothy M Uyeki¹

Affiliations

PMID: 32640147
DOI: 10.1056/NEJMe2022702

Editorial

Baloxavir for Postexposure Prophylaxis against Influenza in Households

Timothy M Uyeki. N Engl J Med. 2020.

. 2020 Jul 23;383(4):389-390.

doi: 10.1056/NEJMe2022702. Epub 2020 Jul 8.

Author

Timothy M Uyeki¹

Affiliation

¹ From the Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta.

PMID: 32640147
DOI: 10.1056/NEJMe2022702

No abstract available

PubMed Disclaimer

Comment on

Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts.
Ikematsu H, Hayden FG, Kawaguchi K, Kinoshita M, de Jong MD, Lee N, Takashima S, Noshi T, Tsuchiya K, Uehara T. Ikematsu H, et al. N Engl J Med. 2020 Jul 23;383(4):309-320. doi: 10.1056/NEJMoa1915341. Epub 2020 Jul 8. N Engl J Med. 2020. PMID: 32640124 Clinical Trial.

Similar articles

Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts.
Ikematsu H, Hayden FG, Kawaguchi K, Kinoshita M, de Jong MD, Lee N, Takashima S, Noshi T, Tsuchiya K, Uehara T. Ikematsu H, et al. N Engl J Med. 2020 Jul 23;383(4):309-320. doi: 10.1056/NEJMoa1915341. Epub 2020 Jul 8. N Engl J Med. 2020. PMID: 32640124 Clinical Trial.
Baloxavir for influenza: Enrichment obscured lack of effect in North-American adults. Author's reply.
de Haas EC, Luijendijk HJ. de Haas EC, et al. Eur J Intern Med. 2020 Feb;72:102. doi: 10.1016/j.ejim.2019.12.021. Epub 2020 Jan 3. Eur J Intern Med. 2020. PMID: 31902562 No abstract available.
Comment to: Baloxavir efficacy in North American Adults.
Portsmouth S, Kawaguchi K, Uehara T, Hayden FG. Portsmouth S, et al. Eur J Intern Med. 2020 Feb;72:99-101. doi: 10.1016/j.ejim.2019.11.005. Epub 2020 Jan 15. Eur J Intern Med. 2020. PMID: 31954593 No abstract available.
Baloxavir: First Global Approval.
Heo YA. Heo YA. Drugs. 2018 Apr;78(6):693-697. doi: 10.1007/s40265-018-0899-1. Drugs. 2018. PMID: 29623652 Review.
Baloxavir marboxil: a novel cap-dependent endonuclease (CEN) inhibitor for the treatment of acute uncomplicated influenza.
Locke SC, Splawn LM, Cho JC. Locke SC, et al. Drugs Today (Barc). 2019 Jun;55(6):359-366. doi: 10.1358/dot.2019.55.6.2999889. Drugs Today (Barc). 2019. PMID: 31250840 Review.

See all similar articles

Cited by

Antiviral Approaches against Influenza Virus.
Kumari R, Sharma SD, Kumar A, Ende Z, Mishina M, Wang Y, Falls Z, Samudrala R, Pohl J, Knight PR, Sambhara S. Kumari R, et al. Clin Microbiol Rev. 2023 Mar 23;36(1):e0004022. doi: 10.1128/cmr.00040-22. Epub 2023 Jan 16. Clin Microbiol Rev. 2023. PMID: 36645300 Free PMC article. Review.
Discovery of a Novel Specific Inhibitor Targeting Influenza A Virus Nucleoprotein with Pleiotropic Inhibitory Effects on Various Steps of the Viral Life Cycle.
Yang F, Pang B, Lai KK, Cheung NN, Dai J, Zhang W, Zhang J, Chan KH, Chen H, Sze KH, Zhang H, Hao Q, Yang D, Yuen KY, Kao RY. Yang F, et al. J Virol. 2021 Apr 12;95(9):e01432-20. doi: 10.1128/JVI.01432-20. Print 2021 Apr 12. J Virol. 2021. PMID: 33627391 Free PMC article.
Novel respiratory infectious diseases in Korea.
Kim HJ. Kim HJ. Yeungnam Univ J Med. 2020 Oct;37(4):286-295. doi: 10.12701/yujm.2020.00633. Epub 2020 Sep 23. Yeungnam Univ J Med. 2020. PMID: 33045803 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information